Stoke Therapeutics, Inc. Common Stock
STOKStoke Therapeutics, Inc. is a biotechnology company focused on developing therapies for genetic disorders by leveraging its proprietary platform to modulate gene expression. The company aims to address underlying genetic causes of diseases through precision oligonucleotide-based interventions.
Company News
Ratings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish ...
Stoke Therapeutics (NASDAQ:STOK) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewha...
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 5% and 26.61%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
